CardioFocus to Present at 30th Annual J.P. Morgan Healthcare Conference
MARLBOROUGH, Mass., Jan. 6, 2012 /PRNewswire/ -- CardioFocus, Inc., developer of the HeartLight™ Endoscopic Ablation System (EAS) for the treatment of atrial fibrillation (AF), announced that it is scheduled to present at the 30th Annual J.P. Morgan Healthcare Conference in San Francisco, CA, on Tuesday, January 10, 2012 at 10:30 a.m. PT.
The presentation by Stephen Sagon, CardioFocus President and CEO, will provide an overview of the company's business, clinical and commercial successes in Europe and news regarding an upcoming U.S. pivotal trial.
The company's HeartLight EAS incorporates an endoscope for direct visualization within a beating heart, in real time and without radiation. It also features a compliant, dynamically adjustable balloon catheter for improved contact with the PV ostium irrespective of individual patient anatomy, and utilizes laser energy for more efficient, durable and precise cardiac ablation.
For more information, please visit www.CardioFocus.com.
About CardioFocus, Inc.
CardioFocus, Inc. is a medical device manufacturer dedicated to advancing ablation treatment for cardiac disorders such as atrial fibrillation (AF). Its novel HeartLight™ Endoscopic Ablation System for catheter ablation incorporates an endoscope to provide physicians with the capacity to see within the heart, and for the first time, visually direct the application of laser energy to achieve durable pulmonary vein isolation.
The HeartLight Endoscopic Ablation System is commercially available at leading institutions throughout Europe. The device is investigational in the U.S., with a pivotal study expected to commence in 2012. CardioFocus is headquartered in Marlborough, MA, USA. For more information on the company and its technology, please visit www.CardioFocus.com.
The scientific information discussed in this news release is preliminary and investigative. The CardioFocus HeartLight Endoscopic Ablation System is not approved by the U.S. Food and Drug Administration (FDA), and no conclusions can or should be drawn regarding the safety or effectiveness of the system. Only FDA can determine whether the product candidates are safe and effective for the use(s) being investigated. Healthcare professionals should refer to/rely upon FDA-approved labeling for the products, and not the information discussed in this news release.
SOURCE CardioFocus, Inc.
More by this Source
US-Zulassungsstudie zu HeartLight® - CardioFocus schließt Patienteneinschreibung ab
Oct 16, 2013, 03:00 ET
CardioFocus Completes Enrollment in HeartLight® U.S. Pivotal Trial
Oct 15, 2013, 06:00 ET
Browse our custom packages or build your own to meet your unique communications needs.
Learn about PR Newswire services
Request more information about PR Newswire products and services or call us at (888) 776-0942.